Femasys Inc (FEMY) Stock Price, Quote & News

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 770 500 3910

Fax: 404 581 5903

Website: www.femasys.com

Address:

3950 Johns Creek Court, Suite 100, Suwanee, United States

TripTrap Feb. 3 at 5:03 PM

$FEMY Traders are trying to fill the gap… Will they close it or will the bulls fend them off?

1 · Reply

David_M_ Feb. 3 at 4:49 PM

$FEMY

0 · Reply

frchmn Feb. 3 at 3:45 PM

$FEMY some hope!

0 · Reply

TripTrap Feb. 3 at 3:26 PM

$FEMY I think there is a good chance this is the bottom. We have significant volume coming in and we gapped up on the open. Almost all major trend changes start or have a gap near their beginnings (breakaway gap). The gap today is between yesterday's close .5160 and today's current low at .5338. There are other reasons I feel this way as well but the bottom line is - if they can keep this mornings gap open then we have found a significant bottom. Let's see how this plays out...

0 · Reply

steve04240 Feb. 3 at 3:26 PM

$FEMY slow and steady...atta girl!

0 · Reply

Bluesir Feb. 3 at 3:17 PM

$FEMY Great news! Nice to have Switzerland on board, it could help much in finding other European Partners. 👍

0 · Reply

JS10gamer007 Feb. 3 at 2:58 PM

$FEMY we are going up and building more confidence we need to break vwap and we will rocket

0 · Reply

steve04240 Feb. 3 at 2:57 PM

$FEMY wonder what the holdup is in the United States

1 · Reply

wolfden2000 Feb. 3 at 2:42 PM

$FEMY today’s press release is very good -Switzerland has a population of about 9 mil. Women 25-60 4.5 million. Nice target audience.

1 · Reply

steve04240 Feb. 3 at 2:26 PM

$FEMY

0 · Reply

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Dec 18, 2025, 9:15 AM EST - 6 weeks ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Nov 25, 2025, 9:15 AM EST - 2 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

Nov 3, 2025, 8:30 AM EST - 3 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Oct 16, 2025, 9:00 AM EDT - 3 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Sep 11, 2025, 9:00 AM EDT - 5 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 8, 2025, 9:00 AM EDT - 5 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Aug 25, 2025, 11:44 PM EDT - 5 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 8, 2025, 4:05 PM EDT - 6 months ago

Femasys Announces Second Quarter Financial Results for 2025

Aug 6, 2025, 9:00 AM EDT - 6 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Jul 1, 2025, 9:00 AM EDT - 7 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jun 25, 2025, 9:00 AM EDT - 7 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 17, 2025, 9:00 AM EDT - 8 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 11, 2025, 9:00 AM EDT - 8 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

May 29, 2025, 4:23 PM EDT - 8 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 8, 2025, 5:01 PM EDT - 9 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 11 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 19, 2025, 9:20 AM EDT - 11 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 18, 2025, 9:00 AM EDT - 11 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 13, 2025, 8:30 AM EDT - 11 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Feb 25, 2025, 9:20 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 20, 2024, 8:15 AM EDT - 2 years ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 6, 2024, 9:00 AM EST - 2 years ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Feb 28, 2024, 9:00 AM EST - 2 years ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 6, 2024, 8:30 AM EST - 2 years ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Jan 26, 2024, 8:00 AM EST - 2 years ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

TripTrap Feb. 3 at 5:03 PM

$FEMY Traders are trying to fill the gap… Will they close it or will the bulls fend them off?

1 · Reply

David_M_ Feb. 3 at 4:49 PM

$FEMY

0 · Reply

frchmn Feb. 3 at 3:45 PM

$FEMY some hope!

0 · Reply

TripTrap Feb. 3 at 3:26 PM

0 · Reply

steve04240 Feb. 3 at 3:26 PM

$FEMY slow and steady...atta girl!

0 · Reply

Bluesir Feb. 3 at 3:17 PM

$FEMY Great news! Nice to have Switzerland on board, it could help much in finding other European Partners. 👍

0 · Reply

JS10gamer007 Feb. 3 at 2:58 PM

$FEMY we are going up and building more confidence we need to break vwap and we will rocket

0 · Reply

steve04240 Feb. 3 at 2:57 PM

$FEMY wonder what the holdup is in the United States

1 · Reply

wolfden2000 Feb. 3 at 2:42 PM

$FEMY today’s press release is very good -Switzerland has a population of about 9 mil. Women 25-60 4.5 million. Nice target audience.

1 · Reply

steve04240 Feb. 3 at 2:26 PM

$FEMY

0 · Reply

TripTrap Feb. 3 at 2:26 PM

$FEMY --NEWS OUT-- February 03, 2026 09:15 ET Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe --| Source: Femasys Inc. https://www.globenewswire.com/news-release/2026/02/03/3231201/0/en/Femasys-Expands-European-Commercial-Footprint-with-Swiss-Partner-for-FemBloc-FemaSeed-and-Portfolio-Products.html

0 · Reply

DARKP00L Feb. 3 at 2:22 PM

$FEMY 09:16 on Feb. 03 2026 Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland #tradeideas

0 · Reply

steve04240 Feb. 3 at 12:55 PM

$FEMY sent an email asking about shareholder value.. typical response I suppose

3 · Reply

4RiskyBusiness4 Feb. 2 at 6:56 PM

$FEMY Key psychological level. Watching closely. Would absolutely add heavy south of here, were that to happen. Likely triple the position.

0 · Reply

JS10gamer007 Feb. 2 at 4:41 PM

$FEMY Borrow Fee: It remains high at 23.5%. This is great for you because it means short sellers are losing money every day they wait for the stock to drop further.

2 · Reply

jabcas Feb. 2 at 4:27 PM

$FEMY I will double down before selling here for sure.

0 · Reply

steve04240 Feb. 2 at 4:17 PM

$FEMY how far are they going to let this get walked down before they throw us a bone (news/update)!?

3 · Reply

JS10gamer007 Feb. 2 at 4:14 PM

$FEMY the big players added shares while the price was dropping. They rarely do this if they expect the company to fail immediately. They are likely providing the "buy wall" at 0.51 you are betting with the house" (Vanguard/UBS) against the retail panic check sec filling

0 · Reply

TripTrap Feb. 2 at 4:05 PM

$FEMY just got this reply back from Nathen Abler in investors relations when I asked about when we could expect the annual 10K out. “Good morning, Femasys expects to report its 4Q2025 results towards the end of March, similar to last year. The company is working to commercialize its product line and increase revenues.” It’s good to know the company is alive and kicking… I admit the slow grind down in price is alarming, but this is when it’s vital to know what you own. Technical signs on the daily chart, of a bottom have not shown up yet, but watching closely.

3 · Reply

TripTrap Feb. 2 at 3:26 PM

$FEMY INTERESTING DATA JUST DISCOVERED from the very end of Q4 13-F filings show major institutional accumulation (right after we plunged at the end of December) VANGUARD added +464K shares UBS added +73K shares Yet we've dropped from $0.67 to $0.52 over the last 9 days on no news. WHAT'S HAPPENING IMO: Classic institutional accumulation during retail capitulation. Smart money buying while weak hands sell due to tax-loss selling, NASDAQ fears, ATM overhang concerns...etc. VANGUARD doesn't chase momentum - they buy conviction plays. 537K combined institutional adds is MATERIAL for 48M float. This creates a hidden support level. Once retail selling exhausts, institutional ownership creates upward bias. Low float + institutional accumulation = potential sharp moves up. BOTTOM LINE: Smart money is accumulating while scared money sells. Price doesn't reflect fundamentals when institutions are adding at these levels.

2 · Reply

TwizzlersForSale Feb. 2 at 3:11 PM

$FEMY two cents away from 50% of $1 Nasdaq listing requirement target. News / updates from management would be great as to what’s going on. NYSE is up 275 points 30min after opening..

0 · Reply

JS10gamer007 Feb. 2 at 1:59 PM

$FEMY lets go heads up and faith boys! bad things are onlY temporary

0 · Reply

Market Cap	31.30M
Revenue (ttm)	1.63M
Net Income (ttm)	-18.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,154.60%
Debt to Equity Ratio	0.02

Volume	619,000
Avg Vol	1,459,772
Day's Range	N/A - N/A
Shares Out	58.48M
Stochastic %K	4%
Beta	-2.54
Analysts	Strong Sell
Price Target	$4.50